# US 10,945,975 B2 · Delaying latency to seizure by combinations of ketone supplements

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 10,945,975 B2
- Document ID: US10945975B2
- Status: Granted
- Kind: B2
- Application number: 16/344,379
- Filed: 2017-10-24
- Published: 2019-08-22
- Granted: 2021-03-16
- Earliest claimed: 2016-10-24
- Assignees: University of South Florida
- Applicants: University of South Florida
- Inventors: Csilla Ari D'Agostino; Dominic Paul D'Agostino; Jay B. Dean
- Web page: https://patentgrep.com/patent/US10945975B2

## CPC

- A61K 31/191: having two or more hydroxy groups, e.g. gluconic acid
- A61K 31/19: Carboxylic acids, e.g. valproic acid (salicylic acid A61K31/60)
- A61K 31/20: having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K 31/225: Polycarboxylic acids
- A61K 33/14: Alkali metal chlorides; Alkaline earth metal chlorides
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/08: Antiepileptics; Anticonvulsants
- A61P 39/00: General protective or antinoxious agents
- A61K 2300/00: Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Provided herein are compositions and methods for preventing central nervous system oxygen toxicity in a subject.

## Claims

### Claim 1

A method of treating or preventing central nervous system oxygen toxicity (CNS-OT) in a subject in need thereof, the method comprising administering a composition comprising a therapeutically effective amount of a ketone ester and a medium chain triglyceride to the subject, wherein administering the composition comprises administering a daily amount of about 1 mg/kg to about 5 g/kg bodyweight of each of the ketone ester and MCT.

### Claim 2 (depends on 1)

The method of claim 1, wherein the composition prevents, delays the onset of, or reduces the severity of tonic-clonic seizures in the subject.

### Claim 3 (depends on 1)

The method of claim 1, wherein the ketone ester is 1,3-butanediol-acetoacetate diester.

### Claim 4 (depends on 1)

The method of claim 1, wherein the ketone ester and the medium chain triglyceride have an approximate 1:1 ratio.

### Claim 5 (depends on 1)

The method of claim 1, wherein the composition further comprises a ketone salt.

### Claim 6 (depends on 5)

The method of claim 5, wherein the ketone salt is a β-hydroxybutyrate salt.

### Claim 7 (depends on 6)

The method of claim 6, wherein the ketone salt is a β-hydroxybutyrate mineral salt.

### Claim 8 (depends on 7)

The method of claim 7, wherein the β-hydroxybutyrate mineral salt is a Na+Ca2+ β-hydroxybutyrate mineral salt.

### Claim 9 (depends on 8)

The method of claim 8, wherein the ketone salt and the medium chain triglyceride have an approximate 1:1 ratio.

### Claim 10

A method of treating or preventing seizures in a subject in need thereof, the method comprising administering a composition comprising a therapeutically effective amount of a ketone ester and a medium chain triglyceride to the subject,
where in administering the composition comprises administering a daily amount of about 1 mg/kg to about 5 g/kg bodyweight of each of the ketone ester and MCT.

### Claim 11 (depends on 10)

The method of claim 10, wherein the composition delays the onset of or reduces the severity of seizures in the subject.

### Claim 12 (depends on 10)

The method of claim 10, wherein the seizure is from epilepsy.

### Claim 13 (depends on 10)

The method of claim 10, wherein the ketone ester is 1,3-butanediol-acetoacetate diester.

### Claim 14 (depends on 10)

The method of claim 10, wherein the ketone ester and the medium chain triglyceride have an approximate 1:1 ratio.

### Claim 15 (depends on 10)

The method of claim 10, wherein the composition further comprises one or more ketogenic compounds is a ketone salt.

### Claim 16 (depends on 15)

The method of claim 15, wherein the ketone salt is κ β-hydroxybutyrate salt.

### Claim 17 (depends on 16)

The method of claim 16, wherein the ketone salt is a β-hydroxybutyrate mineral salt.

### Claim 18 (depends on 17)

The method of claim 17, wherein the β-hydroxybutyrate mineral salt is a Na+Ca2+ β-hydroxybutyrate mineral salt.

### Claim 19 (depends on 15)

The method of claim 15, wherein the ketone salt and the medium chain triglyceride have an approximate 1:1 ratio.

### Claim 20

A method of treating or preventing epileptic seizures in a subject in need thereof, the method comprising administering a composition comprising a therapeutically effective amount of a ketone supplement comprising a ketone ester to the subject.